Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
- Conditions
- Stomach Neoplasms
- Registration Number
- NCT02136836
- Lead Sponsor
- Yonsei University
- Brief Summary
The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 860
Inclusion Criteria
- Histologically confirmed gastric adenocarcinoma
- Patients were diagnosed during 2006-2013
- HER2 expression status was evaluated in primary gastric cancer or metastatic lesion.
Read More
Exclusion Criteria
- Patients with second primary cancer within 5 years
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of HER2 overexpression in gastric cancer patients 8 years
- Secondary Outcome Measures
Name Time Method Gastric cancer specific survival according to HER2 expression in each stage 5 years
Trial Locations
- Locations (1)
Gangnam Severance Hospital
🇰🇷Seoul, Korea, Republic of